Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 14/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9657727 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9450174 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9450172 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL6360245 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9657563 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9449823 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9450167 | 0.88 | OPRK1 (0.75) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL5629630 | 0.87 | OPRK1 (0.77) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL5629605 | 0.85 | OPRK1 (0.62) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9450289 | 0.84 | OPRK1 (0.67) | OPRK1CYP2D6OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | claimed |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-04-11 | — | — | US | claimed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | claimed |
| US-7294647-B2 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | disclosed |
| US-6492351-B1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-6486165-B2 | TREATING WITH AGONISTS AT KAPPA OPIOID RECEPTORS SUCH AS METHYL-4-(2-GLYCYL-4-(TRIFLUOROMETHYLPHENYL)ACETYL)-3-(R,S)-((1 -PYRROLIDINYL)-METHYL)-1-PIPERAZINECARBOXYLATE | ADOLOR CORPORATION | 2002-11-26 | — | — | US | disclosed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6391910-B1 | OPIOID ANTAGONIST; ANALGESIC | ADOLOR CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6303611-B1 | FOR THERAPY OF HYPERALGESIS | ADOLOR CORPORATION | 2001-10-16 | — | — | US | disclosed |
| US-6180623-B1 | USED AS ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION | 2001-01-30 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| US-5981513-A | ADMINISTERING ANTI-PRUITIC COMPOUNDS TO PATIENTS | ADOLOR CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 946/4885OPRM1 3/4885 |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | OPRK1 1/4885CYP2D6 1292/4885OPRM1 8/4885 |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 843/4885OPRM1 3/4885 |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 886/4885OPRM1 3/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 541/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.